year work run leaner faster
compani typic lowest organ growth among peer
standout organ growth quarter better
peer like thermo fisher tmo-buy better consensu estim
revenu quarter yoy beat consensu estim
oper margin versu reflect euroimmun
year progress leaner faster run busi adjust ep ep
beat consensu guidanc estim
discoveri analyst da best quarter three year driven
high singl digit growth appli market doubl digit growth life scienc
mostli bio pharmaceut drug discoveri grew euroimmun
growth doubl digit midteen first half year post doubl
digit us europ china
fy guidanc rais fy adjust ep previou
rais fy core organ growth rate exclud euroimmun
would increas bp fy assum diagnost ad
euroimmun would make discov analyt
fair valu fv reach appli multipl
consolid ep multipl midpoint last two
year forward pe fv also reach appli
da revenu estim per share
dx revenu per share less net debt per share
million except per share data
growth asia estim
yoy growth countri
geograph sale
amort intang
amort intang
amort intang
guid
annual revenu break-out margin
revenu
total sale
revenu
